Related Experiment Videos
[Fibrinolytic and defibrinogenation therapy]
La Ricerca in Clinica E in Laboratorio
|January 1, 1983
Summary
Lowering plasma fibrinogen with fast-acting or slow-acting drugs can prevent and treat thromboembolism. Fast-acting drugs offer fibrinolysis or defibrinogenation, while slow-acting drugs are suitable for long-term microcirculation treatments.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Context:
- Plasma fibrinogen significantly impacts blood viscosity and is implicated in thromboembolic disease.
- Pharmacological strategies to lower fibrinogen are crucial for managing thromboembolic conditions.
Purpose:
- To review the mechanisms and clinical efficacy of fast-acting and slow-acting drugs that lower plasma fibrinogen.
- To explore the role of blood viscosity modulation versus direct anticoagulant/fibrinolytic effects in drug action.
Summary:
- Fast-acting drugs (fibrinolytics, defibrinogenators) rapidly reduce fibrinogen levels, demonstrating efficacy in thromboembolic prevention and treatment.
- Slow-acting drugs (anabolic steroids, clofibrate, etc.) lower fibrinogen gradually and are effective for long-term management of microcirculatory disorders.
- The precise contribution of viscosity reduction versus other mechanisms to the clinical benefits of these drugs requires further elucidation.
Impact:
- Provides a comprehensive overview of fibrinogen-lowering therapies for thromboembolic and microcirculatory disorders.
- Highlights the importance of considering both viscosity and direct pharmacological effects in therapeutic strategies.
- Informs clinical practice and future research directions in cardiovascular and vascular medicine.